Cannabis and psychosis/schizophrenia: human studies

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• The link between cannabis use and psychosis is well-established.
• Cannabinoid receptor research has intensified interest in this association.
• Cannabinoids can induce transient schizophrenia-like symptoms and worsen existing psychotic disorders.

Purpose of the Study:

• To explore the association between cannabis use and psychosis.
• To understand the mechanisms underlying cannabinoid-induced psychosis.
• To identify factors influencing the risk of developing psychotic disorders due to cannabis exposure.

Main Methods:

• Review of current scientific literature on cannabinoid receptor function and psychosis.
• Analysis of evidence regarding transient and long-term effects of cannabinoids on mental health.
• Exploration of potential neurotransmitter pathways (dopamine, GABA, glutamate) involved.

Main Results:

• Cannabinoids can cause temporary positive, negative, and cognitive symptoms in healthy individuals.
• Cannabis use exacerbates symptoms, triggers relapse, and negatively impacts illness course in those with psychotic disorders.
• Cannabis is a component cause, interacting with other factors and potentially genetic predispositions, to increase psychosis risk.

Conclusions:

• Cannabis exposure is a significant factor, but not solely sufficient, in the development of psychotic disorders.
• Dose, duration, age of first use, and genetic interactions are crucial factors in cannabis-related psychosis risk.
• Further research is needed to elucidate the mechanisms, including effects on neurodevelopment, by which cannabis exposure increases psychosis risk.